☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search
Search here
Search here
Subscribe Now
Veru
Veru Reports First Patient Enrollment in the P-IIb Study of Enobosarm Plus Semaglutide for High Quality Weight Loss
May 1, 2024
Veru’s Entadfi Receives the US FDA’s Approval for the Treatment of Benign Prostatic Hyperplasia
December 13, 2021
PharmaShots Weekly Snapshots (Mar 01 - 05, 2021)
March 5, 2021
Load more...
Back to Home
Modal title
×
Modal body text goes here.
